COMP <GO>
GLUE vs PRME // EV/EBITDA & P/E VALUATION
Monte Rosa Therapeutics Inc. (NASDAQ) VS. Prime Medicine Inc. (NASDAQ) • 15-METRIC TALLY: GLUE 1
— PRME 2
■ METRIC PARITY
LAST: $10.87 (+0.18%) • MKT CAP: $927.4M
valuation
—
LAST: $5.24 (-2.24%) • MKT CAP: $950.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GLUE VS. PRME)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GLUE | PRME | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.97% | -17.58% | +14.61 | GLUE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 55.30% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.6 | 61.5 | -16.89 | PRME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $927.4M | $950.4M | -$23.1M | PRME | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GLUE REV | PRME REV | GLUE GROSS % | PRME GROSS % | GLUE FCF | PRME FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $4.6M | — | — | -$27.5M | -$167.1M |
| FY 2024 | $0 | $3.0M | — | — | $38.0M | -$130.2M |
| FY 2023 | $0 | $0 | — | — | -$43.8M | -$165.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GLUE // BETA —
PRME // BETA —